Active	Status	Sponsor type	Region	Phase	Filter
10 Active 3 Inactive 13 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

8 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Birch, David
liMeliGhT, NCT06388200: A Phase 3 Study Of OCU400 Gene Therapy for the Treatment Of Retinitis Pigmentosa	Recruiting	3	150	Canada, US	Sub-Retinal Administration of OCU400-301	Ocugen	Retinitis Pigmentosa	06/25	10/26
NCT04850118: A Clinical Trial Evaluating the Safety and Efficacy of a Single Subretinal Injection of AGTC-501 in Participants With XLRP	Recruiting	2/3	75	Europe, US, RoW	rAAV2tYF-GRK1-hRPGRco, AGTC-501, Control, Untreated Control Group	Beacon Therapeutics	X-Linked Retinitis Pigmentosa	08/25	10/29
OCU400-101, NCT05203939: Study to Assess the Safety and Efficacy of OCU400 for Retinitis Pigmentosa and Leber Congenital Amaurosis	Active, not recruiting	1/2	22	US	OCU400 Low Dose, OCU400 Med Dose, OCU400 High Dose	Ocugen	Retinitis Pigmentosa, Leber Congenital Amaurosis	03/27	03/27
Platypus, NCT05902962: SAD of IVT VP-001 in PRPF31 Mutation-Associated Retinal Dystrophy Subjects	Recruiting	1	20	US	VP-001	PYC Therapeutics	Retinal Dystrophy, PRPF31 Mutationassociated Retinal Dystrophy, RP11	05/24	05/24
NCT05573984: Natural History of PRPF31 Mutation-Associated Retinal Dystrophy	Recruiting	N/A	50	US, RoW		PYC Therapeutics	Retinitis Pigmentosa, Eye Diseases, Hereditary, Retinal Dystrophies, Retinal Dystrophy Rod, Retinal Dystrophy Rod Progressive	12/26	04/27
Locke, Kirsten
liMeliGhT, NCT06388200: A Phase 3 Study Of OCU400 Gene Therapy for the Treatment Of Retinitis Pigmentosa	Recruiting	3	150	Canada, US	Sub-Retinal Administration of OCU400-301	Ocugen	Retinitis Pigmentosa	06/25	10/26
NCT04850118: A Clinical Trial Evaluating the Safety and Efficacy of a Single Subretinal Injection of AGTC-501 in Participants With XLRP	Recruiting	2/3	75	Europe, US, RoW	rAAV2tYF-GRK1-hRPGRco, AGTC-501, Control, Untreated Control Group	Beacon Therapeutics	X-Linked Retinitis Pigmentosa	08/25	10/29
OCU400-101, NCT05203939: Study to Assess the Safety and Efficacy of OCU400 for Retinitis Pigmentosa and Leber Congenital Amaurosis	Active, not recruiting	1/2	22	US	OCU400 Low Dose, OCU400 Med Dose, OCU400 High Dose	Ocugen	Retinitis Pigmentosa, Leber Congenital Amaurosis	03/27	03/27